FAP and nasopharyngeal carcinoma: Figure 1A shows the plasma levels of FAPα in the healthy controls (n = 40) and the patients with diverse cancers (n = 212) respectively, which included liver cancer (n = 37), gastric cancer (n = 32), ESCC (n = 37), CRC (n = 38), nasopharyngeal cancer (n = 34), and lung cancer patients (n = 34) by ELISA.